Latest News & Events
Hemanext Continues European Rollout of Hemanext ONE® RBC Processing and Storage System
Groundbreaking technology to be deployed to transfuse thalassemia patients in Italy and acute...
Hemanext Partners with the Miami Chapter of the Sickle Cell Disease Association of America to Support Local Sickle Cell Disease Community
Partnership Will Expand to Include Educational and Donation Event with OneBlood LEXINGTON, Mass.,...
Hemanext Announces Close of Series B Equity Funding Round
Raises $18 Million in New Equity Financing Appoints Healthcare Luminary Dr. Ismail Kola to Board...
European Patients Have Begun Receiving Transfusions with Hemanext ONE® RBC Processing and Storage System
LEXINGTON, Mass., September 7, 2022, PR NEWSWIRE – Hemanext Inc., a leading innovator in blood...
Current and prospective investors access to the investor Portal
COVID 19 Updates
Follow the course of COVID-19 and locate where to donate blood
View educational material and interesting presentations
Learn about the journey of red blood cells after donation including degradation that occurs during storage and discover the potential of hypoxic storage to alleviate this problem.
The average human body stores about 5.6 liters of blood. As it circulates through the body several times each minute, it accomplishes a variety of functions.
The existence of the storage lesion process has been well established, and recent scientific work has increased the precision and depth.
Numerous studies pertaining to clinical implications of storage lesion suggest a linkage to hyper-coagulability, inflammation, impaired perfusion, immuno-modulation, organ dysfunction13, and mortality14.
Hemanext is developing a technology to enable the storage of RBC under hypoxic conditions. Removing O2 during storage removes the primary “fuel” for oxidative stress1-11.
Learn more about Hemanext and take a closer look at our publications, studies, and posters focused on blood quality and red blood cell characterization.